Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)

Supported by clinical trial proven survival benefit, clinical guidelines recommend upfront autologous stem cell transplantation (ASCT) for eligible MM patients. However, reported real-world utilisation is lower than expected (40–60%). We reviewed ASCT utilisation, demographics and outcomes for MM patients (≤70 years, ≥12-month follow-up) enroled onto the Australian/New Zealand MRDR from June 2012 to May 2020. In 982 patients (<65 years: 684, 65–70 years: 298), ASCT utilisation was 76% overall (<65 years: 83%, 65–70 years: 61%, front-line therapy: 67%). Non-ASCT recipients were older (median age: 65 years vs 60 years, p< 0.001), had more comorbidities (cardiac disease: 16.9% vs 5.4%, p< 0.001; diabetes: 19.1% vs 7.0%, p< 0.001; renal dysfunction: median eGFR(ml/min): 68 vs 80, p< 0.001), inferior performance status (ECOG ≥ 2: 26% vs 13%, p< 0.001) and higher-risk MM (ISS-3: 37% vs 26%, p= 0.009, R-ISS-3 18.6% vs 11.8%, p= 0.051) than ASCT recipients. ASCT survival benefit (median progression-free survival (PFS): 45.3 months vs 35.2 months, p< 0.001; overall survival (OS): NR vs 64.0 months, p< 0.001) was maintained irrespective of age (<65 years: median PFS: 45.3 months vs 37.7 months, p= 0.04, OS: NR vs 68.2 months, p= 0.002; 65–70 years: median PFS: 46.7 months vs 29.2 months, p< 0.001, OS: 76.9 months vs 55.6 months, p= 0.005). This large, real-world cohort reaffirms ASCT survival benefit, including in ‘older’ patients necessitating well-designed studies evaluating ASCT in ‘older’ MM to inform evidence-based patient selection.